Stocks › MRK
Merck & Co., Inc.
MRK·NYSE·
United States·USD
$133.72
+0.91 (+0.69%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
MRK
Merck & Co., Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
MRKS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of MRK by members of U.S. Congress · 463 on record · 25 in the last 12 months
Whale Activity
Position changes in MRK reported for 2026-09-30 by 4078 institutional filers
- Increased1545
- New267
- Held460
- Decreased1543
- Closed101
- No prior filing162
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 228.1M | $33.14B | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 161.5M | $23.47B | increased |
| STATE STREET CORP | 121.4M | $17.75B | increased |
| WELLINGTON MANAGEMENT GROUP LLP | 71.7M | $10.41B | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 68.1M | $9.90B | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 61.6M | $8.93B | increased |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 50.8M | $7.39B | decreased |
| MORGAN STANLEY | 48.2M | $7.01B | decreased |
| FMR LLC | 46.2M | $6.72B | increased |
| JPMORGAN CHASE & CO | 43.1M | $6.44B | decreased |
| Fisher Asset Management, LLC | 41.7M | $6.06B | increased |
| BANK OF AMERICA CORP /DE/ | 30.4M | $4.42B | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by MRK insiders, by quarter · Form 4
Recent Insider Transactions
1,766 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −58.2K | $148.01 | $8.6M | Nov 12, 2026 | Form 4 ↗ |
| Guindo ChirfiEVP, Access, Policy & Comms | Sale | −10.0K | $135.00 | $1.4M | Aug 13, 2026 | Form 4 ↗ |
| Zachary JenniferEVP, General Counsel | Sale | −80.3K | $133.46 | $10.7M | Aug 12, 2026 | Form 4 ↗ |
| Zachary JenniferEVP, General Counsel | Option exercise | +13.4K | $84.71 | $1.1M | Aug 12, 2026 | Form 4 ↗ |
| Zachary JenniferEVP, General Counsel | Option exercise | +41.5K | $117.89 | $4.9M | Aug 12, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −600 | $132.04 | $79K | Aug 12, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −11.1K | $131.61 | $1.5M | Aug 12, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −5,427 | $132.35 | $718K | Aug 11, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −7,410 | $131.33 | $973K | Aug 11, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −20.8K | $130.43 | $2.7M | Aug 10, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −300 | $131.02 | $39K | Aug 6, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −4,945 | $130.23 | $644K | Aug 6, 2026 | Form 4 ↗ |
| DeLuca Richard R.EVP&Pres, Merck Animal Heallth | Sale | −805 | $131.02 | $105K | Aug 6, 2026 | Form 4 ↗ |
| Guindo ChirfiEVP, Access, Policy & Comms | Sale | −15.0K | $131.00 | $2.0M | Aug 6, 2026 | Form 4 ↗ |
| Maraldo David R.EVP & Pres. MMD | Sale | −2,686 | $128.72 | $346K | Aug 5, 2026 | Form 4 ↗ |
| Maraldo David R.EVP & Pres. MMD | Option exercise | +2,686 | $84.71 | $228K | Aug 5, 2026 | Form 4 ↗ |
| Maraldo David R.EVP & Pres. MMD | Sale | −9,709 | $128.72 | $1.2M | Aug 5, 2026 | Form 4 ↗ |
| Maraldo David R.EVP & Pres. MMD | Option exercise | +9,709 | $87.10 | $846K | Aug 5, 2026 | Form 4 ↗ |
| Maraldo David R.EVP & Pres. MMD | Sale | −6,311 | $128.72 | $812K | Aug 5, 2026 | Form 4 ↗ |
| Maraldo David R.EVP & Pres. MMD | Option exercise | +6,311 | $73.73 | $465K | Aug 5, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding MRK · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 78.4M | $10.08B | 0.44% | Jun 30, 2026 |
| VANGUARD 500 INDEX FUND VANGUARD INDEX FUNDS | 64.0M | $8.22B | 0.49% | Jun 30, 2026 |
| Schwab U.S. Dividend Equity ETF SCHWAB STRATEGIC TRUST | 36.2M | $5.35B | 4.76% | Aug 31, 2026 |
| Fidelity 500 Index Fund Fidelity Concord Street Trust | 32.1M | $4.74B | 0.55% | Aug 31, 2026 |
| iShares Core S&P 500 ETF iShares Trust | 34.0M | $4.37B | 0.49% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P 500(R) ETF Trust | 29.9M | $3.85B | 0.49% | Jun 30, 2026 |
| VANGUARD VALUE INDEX FUND VANGUARD INDEX FUNDS | 23.5M | $3.02B | 1.19% | Jun 30, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF SELECT SECTOR SPDR TRUST | 17.4M | $2.24B | 5.52% | Jun 30, 2026 |
| VANGUARD HEALTH CARE FUND VANGUARD SPECIALIZED FUNDS | 16.0M | $2.08B | 5.44% | Jul 31, 2026 |
| VANGUARD DIVIDEND APPRECIATION INDEX FUND VANGUARD SPECIALIZED FUNDS | 14.0M | $1.82B | 1.39% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list MRK's shares (CUSIP 58933Y105), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming merck as client
- MERCK & CO, INC.MERCK & CO INC · 2026 Q3 · HCR, MMM, ANI$2.4M
Filing ↗ - WILLIAMS AND JENSEN, PLLCMERCK & CO INC · 2026 Q3 · HCR, TAX, MMM, PHA$50K
Filing ↗ - AVENUE SOLUTIONSMERCK & CO. INC. · 2026 Q3 · HCR, MMM$50K
Filing ↗ - TARPLIN, DOWNS & YOUNG, LLCMERCK · 2026 Q3 · BUD, HCR, MMM$50K
Filing ↗ - W STRATEGIES, LLCMERCK & CO., INC. · 2026 Q3 · MMM$50K
Filing ↗
Government Contracts
Federal awards to Merck & Co., Inc. · USAspending
No federal contract awards found for Merck & Co., Inc..
U.S. Patents
Recent USPTO applications naming Merck & Co., Inc.
No USPTO patent applications found for Merck & Co., Inc..
Annual Financials
From MRK's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Net income | $18.25B | $17.12B | $365.0M | $14.52B | $13.05B |
| Diluted EPS | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | n/a |
| Cash and equivalents | $14.56B | $13.24B | $6.84B | $12.69B | $8.10B |
| Total assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B |
| Shareholders' equity | $52.61B | $46.31B | $37.58B | $45.99B | $38.18B |
As Merck & Co., Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 24, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 21-for-20Stock splitJun 3, 2021
- 2-for-1Stock splitFeb 17, 1999
- 3-for-1Stock splitMay 26, 1992
- 3-for-1Stock splitMay 26, 1988
- 2-for-1Stock splitMay 27, 1986
- 2-for-1Stock splitJun 1, 1972
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 5.02, 9.01Officer / director changeNov 18, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 29, 2026
EDGAR ↗ - 8-K · Items 5.02Officer / director changeOct 13, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteMay 28, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsMay 22, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsApr 30, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsFeb 3, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsDec 4, 2025
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsOct 30, 2025
EDGAR ↗
About Merck & Co., Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersRAHWAY, NJ
IncorporatedNJ
SEC CIK0000310158 ↗
Former namesMerck & Co. Inc., SCHERING PLOUGH CORP








